Why Alvion?

Developing, manufacturing, and promoting medicines in Europe, MENA, Canada, Australia, South Africa, Australia, Asia and Latin America is the core business model of Alvion. Focusing on delivering innovation and best quality pharmaceuticals among the first companies prior the patent expiry while offering flexible terms and affordable medicines with an effective supply chain is major competitive advantage of Alvion. With a lean management and a team of experienced professionals, Alvion is only aiming high, delivering high growth and exceptional quantitative and qualitative results for all stakeholders.

By developing medicines for its licensing partners, Alvion is an extrovert pharmaceutical company offering a dynamic business model supporting multinational and local partners across a wide territory to succeed by offering its medicines to millions of patients across the world. Producing in state of art manufacturing facilities in Greece, India, UAE and Portugal, Alvion is advancing the supplying chain by entering into co-developing partnerships with finished dosage manufacturers, API producers and R&D centers.

The future of a generic pharmaceutical company rests on creating a flexible, multinational supply chain that overcomes the challenges of the traditional generic business model. Challenging times create real opportunities for a change, new ideas and new approaches. Since its establishment in 2013, Alvion is a preferred partner for leading pharmaceutical companies, establishing one of the most dynamic and fastest growing companies in Southern Europe.